probucol has been researched along with Dyslipidemia in 4 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of probucol on urine albumin excretion in type 2 diabetes mellitus patients with albuminuria using angiotensin-converting enzyme inhibitors or angiotensin receptor blockers." | 5.22 | Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial. ( Baik, SH; Cha, BS; Choi, SH; Chung, CH; Han, KA; Hwang, YC; Jin, SM; Ko, SH; Lee, HW; Lee, IK; Lee, MK; Nam, MS; Park, IeB; Park, TS; Rhee, EJ; Sohn, TS; Yu, JM, 2016) |
| "Regarding patients with familial hypercholesterolemia, those treated with probucol, which is a potent anti-oxidative and anti-hyperlipidemic drug, showed significantly lower Ox-HDL (16." | 1.62 | Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein. ( Inui, H; Kanno, K; Katayama, Y; Koseki, M; Masuda, D; Nishida, M; Ohama, T; Okada, T; Saga, A; Sakata, Y; Sumida, M; Yamashita, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okada, T | 1 |
| Sumida, M | 1 |
| Ohama, T | 1 |
| Katayama, Y | 1 |
| Saga, A | 1 |
| Inui, H | 1 |
| Kanno, K | 1 |
| Masuda, D | 1 |
| Koseki, M | 1 |
| Nishida, M | 1 |
| Sakata, Y | 1 |
| Yamashita, S | 1 |
| Hirata, KI | 1 |
| Jin, SM | 1 |
| Han, KA | 1 |
| Yu, JM | 1 |
| Sohn, TS | 1 |
| Choi, SH | 1 |
| Chung, CH | 1 |
| Park, IeB | 1 |
| Rhee, EJ | 1 |
| Baik, SH | 1 |
| Park, TS | 1 |
| Lee, IK | 1 |
| Ko, SH | 1 |
| Hwang, YC | 1 |
| Cha, BS | 1 |
| Lee, HW | 1 |
| Nam, MS | 1 |
| Lee, MK | 1 |
| Fukumoto, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.[NCT01726816] | Phase 2 | 126 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for probucol and Dyslipidemia
| Article | Year |
|---|---|
Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2016 |
3 other studies available for probucol and Dyslipidemia
| Article | Year |
|---|---|
Development and Clinical Application of an Enzyme-Linked Immunosorbent Assay for Oxidized High-Density Lipoprotein.
Topics: Adult; Antioxidants; Atherosclerosis; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Huma | 2021 |
New Evidence of Probucol on Cardiovascular Events.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Dyslipidem | 2021 |
[Medicines for dyslipidemia].
Topics: Anion Exchange Resins; Arteriosclerosis; Azetidines; Dyslipidemias; Ezetimibe; Fibric Acids; Heart F | 2012 |